AlphAIAlphAI — Financial news for AI agents
seekingalpha.com$IONS

Ionis Pharmaceuticals GAAP EPS of -$0.66 beats by $0.55, revenue of $243M beats by $58.62M (IONS:NASDAQ)

Ionis Pharmaceuticals reported Q3 GAAP EPS of -$0.66, beating estimates by $0.55. Revenue was $243M, up 54.8% year-over-year and $58.62M above expectations. The company saw revenue growth of 55% in Q3 and 64% for the first nine months of 2026 compared to the same periods the prior year.

Original reporting
seekingalpha.com
Published Nov 9, 2026, 12:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 12:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Ionis Pharmaceuticals GAAP EPS of -$0.66 beats by $0.55, revenue of $243M beats by $58.62M (IONS:NASDAQ) — source image
Source · seekingalpha.com
Decision brief

The 30-second read

$IONSNeutralHigh
01

Why it matters

The earnings beat may attract short‑term buying interest, but the negative EPS suggests caution.

02

Market read

First disclosure of Q3 earnings with a strong revenue beat, likely to influence IONS price in after‑hours trading.

03

What to watch

Future guidance and pipeline updates were not disclosed, which could temper enthusiasm.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Ionis Pharmaceuticals is a leading antisense drug developer; its quarterly results are closely watched for pipeline progress.

Company-level read

Ticker impact

$IONSNeutralHigh confidence
Context

Ionis Pharmaceuticals reported Q3 GAAP EPS of -$0.66, beating expectations by $0.55, and revenue of $243M, up 55% YoY, beating estimates by $58.62M.

Expected impact

potential upside as the revenue beat could lift the stock, though the negative EPS may limit gains

Evidence & confidence

First report of the earnings numbers; material revenue beat for a mid‑cap biotech, likely to move the share price in after‑hours trading.

Market effects

Sector

Biotech sector may see modest rally as a peer posts strong revenue growth.

Regional

US biotech stocks could see slight upward pressure in after‑hours trading.

Global

Limited to investors focused on US biotech earnings.

Counterpoint

What could challenge this read

Despite the revenue beat, the continued GAAP loss may keep the stock under pressure.

Key entities

  • Company
    Ionis Pharmaceuticals

    Biotech firm reporting Q3 earnings.

Read at source← All news

StoryIonis cuts TRYNGOLZA outlook after slower launch despite Q3 revenue growth

Also covered by

4 outlets

Related articles

$IONSHighAI 8/10

Here's Why Ionis Pharmaceuticals' Stock is Down 28.5% Post Q3 Earnings

Ionis Pharmaceuticals' stock fell 28.5% post-Q3 2026 earnings despite beating estimates. Investors were disappointed by slower-than-expected Tryngolza sales and reduced full-year guidance to $50M. Wainua royalties also missed estimates. Dawnzera sales grew 40% sequentially. Ionis pushed back positive cash flow target to 2029. Competition from Arrowhead and Alnylam adds to concerns.

tradingview.com
$TEVAHigh

FDA Drug Approvals In October 2026

The FDA approved five drugs in October 2026: Teva's Weltruza (TEVA) for schizophrenia, Asahi Kasei's Hovilpri (3407.T) for herpes, Alcon's Brytly (ALC) for eye redness, GSK and Ionis' Hibsago (GSK, IONS) for hepatitis B, and Xbrane and STADA's Lucamzi for retinal diseases. Key details include efficacy, pricing, and competitor landscape.

rttnews.com
$IONSHighAI 8/10

Ionis Pharmaceuticals Inc (IONS) (Q3 2026) Earnings Call Highlights: DAWNZERA Momentum

Ionis Pharmaceuticals (IONS) reduced 2026 revenue guidance to $50M due to slower TRYNGOLZA launch and Phase III setbacks. Cash flow breakeven delayed to 2029. Only 24% of prescribers have written multiple prescriptions. Management cited education needs and payer coverage as key factors. Q3 cash position was $1.9B, with $1.6B expected by year-end. 2027 guidance deferred to February call.

finance.yahoo.com
$IONSHighAI 8/10

Key facts: Ionis Q3 Loss, Mixed Trial Results; HIBSAGO Wins Approvals

Ionis Pharmaceuticals (IONS) reported Q3 2026 revenue of $243M, up 54.8% YoY, and a net loss of $110M. It lowered TRYNGOLZA sales guidance to $50M. Mixed trial results: sefaxersen and ulefnersen showed positive data, while pelacarsen and eplontersen missed Phase 3 goals. HIBSAGO won U.S., Japan, and Canada approvals, triggering a $30M milestone. The average 12-month price target fell to $83.38, with a consensus Buy rating.

tradingview.com